Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods, MSc, Neil Hawkins, PhD, William Dunlop, MEc, Alison O'Toole, MB BS, FRCA, PhD, MFPM, Steve Bramham-Jones, DipAM Value in Health Volume 15, Issue 5, Pages (July 2012) DOI: /j.jval Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions
Fig. 1 Value in Health , DOI: ( /j.jval ) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions
Fig. 2 Value in Health , DOI: ( /j.jval ) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions
Fig. 3 Value in Health , DOI: ( /j.jval ) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions
Fig. 4 Value in Health , DOI: ( /j.jval ) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions
Fig. 5 Value in Health , DOI: ( /j.jval ) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions
Fig 6 Value in Health , DOI: ( /j.jval ) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions